EVERETT, Wash., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Coastal Financial Corporation (Nasdaq: CCB) (the “Company”, "Coastal", "we", "our", or "us"), the holding company for Coastal Community Bank (the “Bank”), through which it operates a community-focused bank segment ("community bank") with an industry leading banking as a service ("BaaS") segment ("CCBX"), today reported unaudited financial results for the quarter ended September 30, 2025, including net income of $13.6 million, or $0.88 per diluted common shar ...

TORONTO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Evergold Corp. (TSX-V: EVER, WKN: A2PTHZ) (“Evergold” or the “Company”) is pleased to announce that C.J. Greig Holdings Ltd., a company wholly-owned by C.J. “Charlie” Greig, a director of the Company and Evergold’s Chief Exploration Officer (the “Investor”), has agreed to subscribe for up to $350,000 (the “Offering”) of an unsecured convertible debenture (the “Debenture”). The Debenture bears interest at a rate of 7.5% per annum and will mature on December 31, 2026 ...

SATO Corporation, Stock Exchange Release 29 October 2025 at 1:00 pm SATO Corporation’s financial reports and AGM in 2026In 2026, SATO will publish its financial reports according to the following schedule: 6 February 2025Financial Statements Release for 20258 May 2026Interim Report for 1 January–31 March 2026 (Q1)14 July 2026Half-year Report for 1 January–30 June 2026 (H1)23 October 2026Interim Report for 1 January–30 September 2026 (Q3) The Annual Report for 2025 will be published on SATO’s website at www ...

Group 1 - Mowi has acquired a controlling stake in Nova Sea from Vigner Olaisen AS, as announced on 21 October 2025 [1] - 30% of the purchase price for the acquisition has been settled through the issuance of new shares in Mowi, totaling 10,179,505 new shares issued to Vigner Olaisen AS [2] - Following the share issuance, Mowi's new share capital is NOK 3,954,679,470, divided into 527,290,596 shares, each with a nominal value of NOK 7.50 [2]

Core Viewpoint - Navient has released its financial results for the third quarter of 2025, indicating ongoing efforts to manage the cost of higher education for students and families [1]. Financial Results - The complete financial results for the third quarter of 2025 are available on Navient's investor website [1]. - A live audio webcast discussing these results will be hosted by the CEO and CFO on October 29, 2025, at 8 a.m. ET [1]. Company Overview - Navient focuses on helping students and families manage higher education costs through responsible lending, flexible refinancing, and trusted servicing [3]. - The company emphasizes creating long-term value for customers and investors, supported by decades of portfolio management expertise [3].

Core Insights - Gildan Activewear Inc. reported a strong third quarter for 2025, with net sales reaching $911 million, a 2.2% increase year-over-year, driven by a 5.4% growth in Activewear sales [3][7]. - The company achieved record adjusted diluted EPS of $1.00, reflecting a 17.6% increase from the previous year [9][21]. - Gildan's merger agreement with HanesBrands is expected to close by early 2026, which is anticipated to enhance its market position [16][17]. Financial Performance - Net sales for Q3 2025 were $911 million, with Activewear sales at $831 million, up 5.4% due to favorable product mix and higher prices [3][32]. - Gross profit for the quarter was $307 million, representing 33.7% of net sales, an improvement from 31.2% in the prior year [4][30]. - Operating income was $192 million, or 21.1% of net sales, slightly down from 21.7% in the previous year, but adjusted operating income increased to $212 million, or 23.2% of net sales [6][31]. Expense Management - SG&A expenses rose to $95 million, up from $84 million in the prior year, primarily due to higher variable compensation and IT-related expenses [5][12]. - Net financial expenses increased to $44 million, attributed to fees related to financing for the HanesBrands acquisition [8][14]. Year-to-Date Results - Year-to-date net sales reached $2,541 million, a 3.7% increase compared to the same period last year, with Activewear sales up 8.7% [10][11]. - Gross margin improved to 32.2%, up 150 basis points year-over-year, driven by lower raw material costs and favorable pricing [11][30]. - Adjusted diluted EPS for the year-to-date was $2.55, a 17% increase from the previous year [14][46]. Merger and Acquisition - The merger with HanesBrands is valued at approximately $2.2 billion in equity and $4.4 billion in enterprise value, with Gildan shareholders set to receive shares and cash for their HanesBrands stock [16][17]. - The transaction is expected to enhance Gildan's capabilities and market reach, aligning with its growth strategy [2][18]. 2025 Guidance Update - The company updated its full-year guidance, projecting revenue growth in the mid-single digits and adjusted diluted EPS in the range of $3.45 to $3.51, reflecting a 15% to 17% year-over-year increase [21][19]. - Free cash flow is expected to be approximately $400 million, down from previous guidance of above $450 million [21][19]. Dividend Declaration - The Board of Directors declared a cash dividend of $0.226 per share, payable on December 15, 2025, to shareholders of record as of November 19, 2025 [22]. ESG Recognition - Gildan was recognized as one of Canada's Best 50 Corporate Citizens for the fourth consecutive year and featured on TIME's World's Most Sustainable Companies list [20].

Core Insights - Chart Industries, Inc. reported a significant increase in orders and sales for the third quarter of 2025, with orders reaching $1.68 billion, a 43.9% increase compared to the same period in 2024 [4][7]. - The company is in the process of being acquired by Baker Hughes, with a definitive agreement for Baker Hughes to acquire all outstanding shares of Chart's common stock for $210 per share in cash [1][15]. - The company recorded a termination fee expense of $266 million related to a previously proposed merger with Flowserve, impacting reported operating income [1][34]. Financial Performance - Total sales for the third quarter of 2025 were $1.1 billion, reflecting a 3.6% increase year-over-year, with a notable increase of 9.7% when excluding the Repair, Service and Leasing segment [6][8]. - The adjusted operating income margin reached a record 22.9%, with gross profit as a percentage of sales remaining flat at 34.1% [7][8]. - Reported diluted earnings per share (EPS) were ($3.23), but adjusted EPS increased by 27.5% to $2.78 compared to the third quarter of 2024 [8]. Segment Performance - Cryo Tank Solutions (CTS) saw orders decrease by 8.0% to $116.1 million, with sales declining by 7.0% to $151.2 million due to lower industrial gas sales [9]. - Heat Transfer Systems (HTS) experienced a significant increase in orders, up 79.1% to $760.8 million, and sales increased by 36.3% to $349.3 million, driven by demand in LNG and data centers [10]. - Specialty Products orders grew by 84.4% to $438.5 million, although sales decreased by 4.7% to $269.9 million due to timing issues and non-repeat of higher sales from the previous year [11]. - The Repair, Service and Leasing segment saw orders decrease by 3.4% to $365.0 million, with sales declining by 8.4% to $330.2 million [12]. Balance Sheet and Cash Flow - The company reported net cash from operating activities of $118.0 million, resulting in free cash flow of $94.7 million after capital expenditures of $23.3 million [13]. - The net leverage ratio improved to 2.78, down from 2.85 in the previous quarter and 3.04 in the same quarter last year [13]. - Total assets increased to $9.79 billion as of September 30, 2025, compared to $9.12 billion at the end of 2024 [29]. Acquisition Details - The acquisition by Baker Hughes was approved by approximately 99% of Chart's shareholders on October 6, 2025, with the transaction expected to close by mid-2026 [15][16]. - The merger agreement stipulates that Chart shareholders will receive $210 per share in cash upon completion of the transaction [15].

Core Insights - Kyverna Therapeutics announced positive interim data from the Phase 2 portion of the KYSA-6 clinical trial for KYV-101 in generalized myasthenia gravis (gMG), achieving 100% clinically meaningful responses in primary endpoints [1][2][5] - The results indicate that KYV-101 can provide rapid and durable symptom improvement with a single dose, potentially leading to drug-free, disease-free remission [2][5][10] Efficacy - 100% of patients (6 out of 6) achieved clinically meaningful reductions in Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores, with mean reductions of -8.0 points and -7.7 points at 24 weeks, respectively [6][12] - Deep responses were observed as early as two weeks post-treatment, indicating rapid efficacy [6][12] Safety - KYV-101 was well-tolerated, with no high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) reported [12] - One patient experienced a serious adverse event of Grade 4 neutropenia, which improved with standard supportive care [12] Clinical Trial Design - The Phase 2 portion of the KYSA-6 trial is a single-arm, open-label, multicenter study focusing on the efficacy and safety of KYV-101 in gMG [3][8] - The trial was amended to a registrational Phase 2/3 study following discussions with the FDA [8] Future Plans - The company plans to initiate enrollment for the Phase 3 portion of the trial by the end of the year and will share updated data from the Phase 2 portion next year [5][12] - Kyverna aims to establish a first-in-class neuroimmunology franchise and expand growth opportunities across multiple autoimmune indications [2][13]

Core Insights - NetraMark Holdings Inc. is leveraging its AI technology, NetraAI, to enhance clinical trials in the pharmaceutical industry, particularly for major depressive disorder (MDD) [1][10] Group 1: Presentation Highlights - At the ISCTM Autumn conference and ECNP Congress, NetraMark showcased two significant applications of its technology, focusing on ketamine and escitalopram trials [1][5] - The first presentation demonstrated how NetraAI identified distinct patient responder subgroups in ketamine trials, revealing that ketamine responders had unique baseline characteristics compared to placebo responders [2][3] - The second presentation introduced a novel algorithm that improved predictive accuracy in heterogeneous MDD trials, specifically for escitalopram response, by identifying a compact feature set related to anhedonia and mood [5][6] Group 2: Key Findings - In the ketamine trial, responder subgroups diverged significantly from placebo responders by the second infusion, indicating that ketamine's efficacy is not merely due to functional unblinding [4][8] - NetraAI's analysis in the CAN-BIND trial reduced clinical variables from 718 to 8 key variables, enhancing prediction accuracy and identifying a subgroup of highly predictive responders [9][7] - The technology revealed a genetic signature linked to neuroplasticity, allowing for a 91% accuracy in predicting treatment success when retrained on specific features [17] Group 3: Implications for Clinical Trials - NetraAI's capabilities can help overcome traditional barriers in CNS drug development by improving patient stratification, reducing placebo-related noise, and enhancing predictive modeling [10][12] - The advancements in distinguishing true pharmacologic effects from placebo responses represent a significant step forward in the design and interpretation of psychiatric and CNS trials [11][12] - As precision medicine becomes increasingly important, NetraMark's innovations provide a robust toolkit for pharmaceutical companies to uncover meaningful patient subgroups and accelerate drug development timelines [12][14]

Core Insights - Verizon Communications Inc. reported third-quarter 2025 results, indicating a positive trajectory towards achieving full-year financial guidance [1][9] - CEO Dan Schulman emphasized a shift to a customer-first culture and aggressive transformation of the company's operations and financial profile [2] Financial Performance - Earnings per share (EPS) for Q3 2025 was $1.17, up from $0.78 in Q3 2024; adjusted EPS was $1.21 compared to $1.19 in Q3 2024 [7][24] - Total operating revenue reached $33.8 billion, reflecting a year-over-year increase of 1.5% [7] - Consolidated net income for Q3 2025 was $5.1 billion, compared to $3.4 billion in Q3 2024 [7] - Cash flow from operating activities for the first nine months of 2025 was $28.0 billion, up from $26.5 billion in the same period of 2024 [7] - Free cash flow for the first nine months of 2025 was $15.8 billion, an increase from $14.5 billion in 2024 [7] Revenue Segments - Wireless service revenue grew to $21.0 billion in Q3 2025, marking a 2.1% increase year-over-year [7] - Verizon Consumer revenue totaled $26.1 billion in Q3 2025, up 2.9% year-over-year [7] - Total Verizon Business revenue was $7.1 billion in Q3 2025, a decrease of 2.8% year-over-year [11] Subscriber Metrics - Consumer wireless retail postpaid churn was 1.12% in Q3 2025, while wireless retail postpaid phone churn was 0.91% [11] - Verizon delivered 306,000 broadband net additions in Q3 2025, with total broadband connections exceeding 13.2 million, representing an 11.1% increase year-over-year [7][11] - Business reported 110,000 wireless retail postpaid net additions in Q3 2025, including 51,000 postpaid phone net additions [11] Debt and Financial Ratios - Total unsecured debt at the end of Q3 2025 was $119.7 billion, down from $126.4 billion at the end of Q3 2024 [7] - The ratio of unsecured debt to consolidated net income (LTM) was 5.9 times, and net unsecured debt to consolidated adjusted EBITDA ratio was 2.2 times [7][22] Outlook and Guidance - Verizon remains confident in its full-year guidance, expecting capital expenditures to be within or below the previously guided range of $17.5 billion to $18.5 billion [9][12] - The company anticipates total wireless service revenue growth of 2.0% to 2.8% and adjusted EBITDA growth of 2.5% to 3.5% for the full year [12]